Bone Biologics CORP Form 4 insider transactions

Bone Biologics Corp's CFO, Deina Walsh, was granted 8,335 employee stock options with an exercise price of $1.55, effective January 8, 2026.

Bone Biologics Corp's CEO, Jeff Frelick, reported the acquisition of new employee stock options and beneficial ownership of common stock.

Bone Biologics Corp. Director Phillip Meikle II was granted 62,894 non-employee stock options at an exercise price of $0.88, vesting quarterly over one year.

Bone Biologics Corp. Director Siddhesh Rajendra Angle reported the grant of new stock options and updated his beneficial ownership of derivative securities in a recent SEC Form 4 filing.

Bone Biologics Corp. Director Bruce Stroever was granted 62,894 non-employee stock options with an exercise price of $0.88, vesting quarterly over one year.

Bone Biologics Corp. Director Robert E. Gagnon has reported the acquisition of 62,894 non-employee stock options at an exercise price of $0.88, granted on June 4, 2025, under the company's 2015 Equity Incentive Plan.

Bone Biologics CEO Jeff Frelick reports the acquisition of 54,110 stock options and existing holdings.

Chief Financial Officer of Bone Biologics Corp, Deina Walsh, reports the acquisition of 27,055 stock options and 1,875 common stock.

Director Phillip Terry Meikle II acquired stock options in Bone Biologics Corp on October 16, 2024.

Bruce Stroever, a director of Bone Biologics Corp, reports the acquisition of stock options.

Robert E. Gagnon, a director of Bone Biologics Corp, reports the acquisition of stock options.

Director Siddhesh Rajendra Angle reports acquisition of stock options in Bone Biologics Corp.